Zim Laboratories Limited (NSE:ZIMLAB) filed an intimation on 4 August 2026 under Regulation 30 of SEBI LODR Regulations, 2015, disclosing that its Q1FY27 Earnings Conference Call is scheduled for Friday, 7 August 2026, at 12:00 PM IST, hosted by Go India Advisors.
Key Highlights
- The Q1FY27 Earnings Conference Call is scheduled for Friday, 7 August 2026, at 12:00 PM IST, hosted by Go India Advisors on behalf of Zim Laboratories Limited.
- Director (Finance) Mr. Zulfiquar Kamal and Chief Financial Officer Mr. Shyam Mohan Patro are confirmed company participants for the call.
- Dial-in numbers provided are 086 3416 8787 and 086 4536 6906, with a pre-registration option available to participants via a Diamond Pass link.
- The filing was submitted to both BSE (Company Code 541400) and NSE (Symbol: ZIMLAB) under Regulation 30 read with Schedule III of SEBI LODR Regulations, 2015.
About the Company
Zim Laboratories Limited (NSE:ZIMLAB), headquartered in Nagpur, Maharashtra, is a pharmaceutical company engaged in the development and manufacture of novel oral drug delivery systems, including thin-film strips, chewable tablets, and other innovative dosage forms. Its manufacturing works are located in the MIDC area at Kalmeshwar, Nagpur district, and it operates under CIN L99999MH1984PLC032172.
Announcement in Detail
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Zim Laboratories Limited notified both BSE and NSE on 4 August 2026 that a Q1FY27 Earnings Conference Call will be conducted on 7 August 2026 at 12:00 PM IST. The call is being hosted by Go India Advisors, and participants are advised to dial in at least five to ten minutes before the scheduled start time.
Company participants named in the filing include Mr. Zulfiquar Kamal, Director (Finance), Mr. Shyam Mohan Patro, Chief Financial Officer, and Mr. Zain Daud from Investor Relations. For coordination queries, Go India Advisors contacts Deepika Sharma and Sheetal Khanduja have been listed in the announcement.
Impact on Investors
Investors will note that this announcement is a procedural disclosure under Regulation 30 of SEBI LODR Regulations and does not itself contain any financial results or guidance for Q1FY27. The scheduled conference call on 7 August 2026 will be the forum through which the company's senior management, including the CFO and Director (Finance), address performance-related matters, and shareholders will observe that the filing confirms the identities of the participating executives in advance.
The disclosed dial-in details and pre-registration option indicate the call is open for broader investor participation, which provides retail and institutional shareholders an opportunity to access management commentary directly once Q1FY27 results are formally disclosed.
Sector / Market Context
India's pharmaceutical sector continues to be a significant contributor to the country's export profile, with the industry supplying generics and specialty formulations to regulated markets globally. The growing adoption of novel drug delivery technologies, including oral thin films, represents an area of focused product development activity across mid-sized Indian pharma manufacturers, a segment in which Zim Laboratories operates through its Kalmeshwar facility.